摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Bromo-1-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]ethanone | 1353570-01-0

中文名称
——
中文别名
——
英文名称
2-Bromo-1-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]ethanone
英文别名
2-bromo-1-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]ethanone
2-Bromo-1-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]ethanone化学式
CAS
1353570-01-0
化学式
C13H13BrN2O2
mdl
——
分子量
309.162
InChiKey
RJTDNBOWZHHUNX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    44.1
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS
    申请人:Wagner Steven L.
    公开号:US20130165416A1
    公开(公告)日:2013-06-27
    The invention provides a novel compound having a structure corresponding to Formula (I): (A)-(B)—(C)-(D)  (I) or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.
    本发明提供了一种新型化合物,其结构对应于公式(I):(A)-(B)-(C)-(D)(I),或其药学上可接受的盐或前药,并提供其使用方法。
  • US9403815B2
    申请人:——
    公开号:US9403815B2
    公开(公告)日:2016-08-02
  • Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators
    作者:Kevin D. Rynearson、Ronald N. Buckle、R. Jason Herr、Nicholas J. Mayhew、Xinchao Chen、William D. Paquette、Samuel A. Sakwa、Jinhai Yang、Keith D. Barnes、Phuong Nguyen、William C. Mobley、Graham Johnson、Juinn H. Lin、Rudolph E. Tanzi、Steven L. Wagner
    DOI:10.1016/j.bmc.2020.115734
    日期:2020.11
    The evolution of gamma-secretase modulators (GSMs) through the introduction of novel heterocycles with the goal of aligning activity for reducing the levels of Aβ42 and properties consistent with a drug-like molecule are described. The insertion of a methoxypyridine motif within the tetracyclic scaffold provided compounds with improved activity for arresting Aβ42 production as well as improved properties, including solubility. In vivo pharmacokinetic analysis demonstrated that several compounds within the novel series were capable of crossing the BBB and accessing the therapeutic target. Treatment with methoxypyridine-derived compound 64 reduced Aβ42 levels in the plasma of J20 mice, in addition to reducing Aβ42 levels in the plasma and brain of Tg2576 mice.
  • [EN] COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS DANS LA MODULATION DES NIVEAUX DE DIFFÉRENTES ALLOFORMES DU PEPTIDE AMYLOÏDE BÊTA
    申请人:UNIV CALIFORNIA
    公开号:WO2011163636A3
    公开(公告)日:2012-04-19
查看更多